Table 1 Correlations between TXNDC9 expression and clinicopathologic variables
Variables | TXNDC9 expression in HCC | p | |
|---|---|---|---|
Negative (n = 61, %) | Positive (n = 147, %) | ||
Gender | 0.871 | ||
Male | 52 (85.2%) | 124 (84.4%) | |
Female | 9 (14.8%) | 23 (15.6%) | |
Age | 0.403 | ||
≤50 years | 35 (57.4%) | 75 (51.0%) | |
>50 years | 26 (42.6%) | 72 (49.0%) | |
Hepatitis B virus DNA | 0.822 | ||
≤5 log10 copies/mL | 51 (83.6%) | 121 (82.3%) | |
>5 log10 copies/mL | 10 (16.4%) | 26 (17.7%) | |
AFP | 0.109 | ||
≤200 ng/mL | 34 (55.7%) | 64 (43.5%) | |
>200 ng/mL | 27 (44.3%) | 83 (56.5%) | |
Cirrhosis | 0.725 | ||
No | 9 (14.8%) | 19 (12.9%) | |
Yes | 52 (85.2%) | 128 (87.1%) | |
Tumor number | 0.188 | ||
Single | 44 (72.1%) | 92 (62.6%) | |
Multiple | 17 (27.9%) | 55 (37.4%) | |
Tumor size | 0.013 | ||
≤5 cm | 32 (52.5%) | 50 (34.0%) | |
>5 cm | 29 (47.5%) | 97 (66.0%) | |
Portal vein invasion | 0.461 | ||
No | 52 (85.2%) | 119 (81.0%) | |
Yes | 9 (14.8%) | 28 (19.0%) | |
Tumor differentiation | 0.022 | ||
Well and moderate | 44 (72.1%) | 81(55.1%) | |
Poor | 17 (27.9%) | 66 (44.9%) | |
TNM stage | 0.035 | ||
I–II | 38 (62.3%) | 68 (46.3%) | |
III–IV | 23 (37.7%) | 79 (53.7%) | |
